OncoMatch/Clinical Trials/NCT06467617
Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC
Is NCT06467617 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab for non small cell lung cancer.
Treatment: Adebrelimab plus albumin-bound paclitaxel, carboplatin and recaticimab — Current studies confirmed that the immune perioperative treatment with combination chemotherapy curative effect and safety of resectable NSCLC, but its short-term curative effect and long-term survival benefit remains to be further improved to explore the new way of immune combination therapy. Experimental study showed that the inhibition of PCSK9 could significantly increase in tumor cells of the immune response in mice, inhibit the PCSK9 enhanced anti-tumor immune response of mice can be further coordinate with immune checkpoint therapy, forming a lasting anti-tumor immune effect. There are no reports on the peri-operative treatment of immune combined with chemotherapy and PCSK-9 inhibitors in patients with resectable NSCLC. Based on the above, the aim of this study is to explore the efficacy and safety of Adebrelimab combined with recaticimab and chemotherapy in the perioperative treatment of patients with resectable NSCLC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Excluded: EGFR mutation
Known EGFR or ALK mutation
Excluded: ALK mutation
Known EGFR or ALK mutation
Disease stage
Required: Stage II, IIIA, T3N2M0 IIIB (UICC and AJCC 8th edition TNM)
operable stage II-III NSCLC (stages II, IIIA, and T3N2M0 IIIB) according to the UICC and AJCC 8th edition TNM staging system. Non-massive metastases (short diameter ≤2cm Lymph nodes) with expected complete resectable N2
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Lab requirements
Blood counts
ANC ≥ 1.8 x 10^9/L; Hb ≥ 100 g/L; PLT ≥ 125 x 10^9/L
Kidney function
Serum creatinine ≤ 1.5 ULN, endogenous creatinine clearance ≥ 50 ml/min (Cockcroft-Gault formula)
Liver function
ALT, AST ≤ 2.5 ULN; TBIL ≤ 1.5 ULN
Cardiac function
No grade II or higher myocardial ischemia or infarction, poorly controlled arrhythmia, NYHA class III-IV cardiac insufficiency, LVEF < 50%, recent (6 months) MI or heart failure, uncontrolled angina, severe ventricular arrhythmia, or clinically significant cardiac disease
Normal main organs function, should meet the following criteria: (1) the blood routine examination shall meet within 14 days (without blood transfusion, hematopoietic factor not used and unused drugs to correct) a. ANC≥1.8 x 10^9 / L; B. Hb≥100 g/L; C. PLT ≥ 125×10^9/L; (2) Biochemical examination must meet the following criteria: a. TBIL ≤ 1.5ULN; B. ALT、AST≤2.5 ULN; Serum creatinine sCr≤1.5ULN, endogenous creatinine clearance≥50ml/min (Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify